Sign in
Taking people in United StatesPhase 1/2

Tests DOC1021 dendritic cell immunotherapy in adults with refractory melanoma

Tests DOC1021 immunotherapy, made from patients' own blood cells, in adults with melanoma.

Key facts

Who runs it
Diakonos Oncology Corporation
Where
Birmingham, Boston, Chapel Hill, Dallas, Duarte, Gilbert, Morristown, and Scottsdale, United StatesSee the 8 sites
Trial code
Registry title
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Status
Recruiting
Phase
Phase 1/2
People taking part
35 people, planned
Started
6 Apr 2026
Expected to end
Jan 2033
Type of study
Interventional
Treatments tested
  • DOC1021
  • Tumor resection
  • pIFN (peginterferon alfa-2a)
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that cannot be removed by surgery or has spread, and that kept growing after earlier treatment including anti-PD-1.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Melanoma that cannot be removed by surgery or has spread. It progressed after at least 1 earlier systemic therapy that included anti-PD-1. Brain metastases are allowed if stable after treatment.
Earlier treatment
Must have had at least 1 earlier systemic therapy including anti-PD-1. Must be willing to hold anti-PD-1 from enrollment until at least 6 weeks after the first DOC1021 dose. No other investigational drug within the last 30 days.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Active HIV or hepatitis infection
  • Severe or uncontrolled medical condition, such as severe heart disease or autoimmune disease needing immune-suppressing drugs
  • Leftover side effects from earlier immunotherapy worse than Grade 1
  • Another investigational drug within the last 30 days

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and avail-ability for the duration of the study
  • Age 18 years or older
  • Patients diagnosed with unresectable or metastatic melanoma and progressed following ≥1 prior systemic therapy including anti-PD-1 (i.e., refractory to anti-PD-1). Refractory defined as primary or secondary resistance as per SITC guidelines, except that confirmatory scan not required if clinical progression requiring surgery or radiation to relieve symptoms
  • Willing and able to withhold anti-PD-1 treatment from the time of enrollment through at least 6 weeks after the first DOC1021 administration
  • One or more lesions available for biopsy or resection expected to yield at least 50 mg and preferably 100 mg of tumor for generating DOC1021 and at least 1 measurable target tumor lesion evaluable after DOC1021 by RECIST version 1.1
  • Brain metastases allowed if stable after prior treatment
  • Ability to receive leukapheresis (with filgrastim if clinically indicated) and perinodal injections of DOC1021 near regional nodes + weekly pIFN x 4 weeks (i.e., sufficient clinical stability and anticipated life expectancy to complete the treatment period and allow time for an immune response to develop)
  • Females of reproductive potential must have a negative serum pregnancy test and agree to use effective contraception (as deter-mined appropriate for the patient by the investigator) during study treatment
  • Adequate kidney, liver, bone marrow function, and immune function, as follows:; Hemoglobin ≥ 8.0 gm/dL (use of transfusion or other intervention to achieve is acceptable); Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; Platelet count ≥ 75,000/mm3; Calculated creatinine clearance (CrCl) > 30 mL/min using Cockcroft and Gault formula:; For males = (140 - age[years]) x (body weight [kg]) / (72 x serum creatinine [mg/dL]) ii. For females = 0.85 x value from male formula e. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) except in patients with Gilbert's disease for which total bilirubin must be ≤ 3 times ULN f. Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) ≤ 3 times the ULN (or ≤ 5.0 × ULN if liver metastases)
  • Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1

Who cannot take part

  • Residual immune-related toxicities from prior immunotherapy > Grade 1 severity. However, patients who experienced prior endocrine toxicity are eligible if well-controlled on replacement therapy
  • Treatment with another investigational drug or other experimental intervention within the last 30 days
  • Known active HIV or hepatitis infection. Patients with HIV that is well-controlled and have undetectable viral titers remain eligible. Patients with history of HCV adequately treated such that RNA viral load is negative also remain eligible
  • Any severe or uncontrolled medical condition or other condition that could affect participation in this study as determined by the investigator, including but not limited to uncontrolled or severe cardiac dis-ease, systemic autoimmune disorders requiring immunosuppression*, autoimmune hyper/hypothyroidism, untreated viral hepatitis, autoimmune hepatitis (*autoimmune disorders include but are not limited to rheumatoid arthritis, psoriasis and inflammatory bowel disease and immunosuppressive medications include DMARDs like methotrexate, TNF inhibitors, IL-6 receptor blockers, CD80/86 inhibitors, anti-CD20 and JAK inhibitors)
  • Patients who are pregnant or breastfeeding

Where in United States

  • The University of Alabama at BirminghamBirmingham, United StatesContact: Luke HannaTaking people
  • Massachusetts General Hospital Cancer InstituteBoston, United StatesContact: Kathryn CioffiTaking people
  • University of North CarolinaChapel Hill, United StatesContact: Claire KowalczykTaking people
  • UT SouthwesternDallas, United StatesContact: Desiree PierreTaking people
  • City of HopeDuarte, United StatesContact: Doni WooTaking people
  • Banner MD Anderson Cancer CenterGilbert, United StatesContact: Mayra MadridTaking people
  • Atlantic HealthMorristown, United StatesContact: Maureen NowakowskiTaking people
  • Arizona State University-Honor Health Research InstituteScottsdale, United StatesContact: Ashley AllisonTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells.

Read full original descriptionShow less

The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single-arm phase II cohort to assess efficacy of the treatment regimen.

All participants will:

* Undergo a leukapheresis collection (take filgrastim subcutaneously x 5 doses, if clinically necessary, leading up to collection) * Receive two doses of DOC1021 under image guidance 2 weeks apart * Receive subcutaneous pIFN injections weekly for a total of 4 doses in parallel with the DOC1021 injections * Undergo an optional image-guided perinodal DOC1021 booster injection approximately 6 months after the first DOC1021 dose along with additional subcutaneous pIFN injections at time of the booster and the subsequent week for a total of 2 pIFN doses * Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive optional treatment with anti-PD1 agents

The group in the trial

  • Experimental: DOC1021 + pIFNTreatment being tested

    DOC1021 administered by injection near active tumor lesion lymph nodes + pIFN

    Treatment: DOC1021, Tumor resection, and pIFN (peginterferon alfa-2a)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Plain-language title
Tests DOC1021 dendritic cell immunotherapy in adults with refractory melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
9 September 2026